Ceftazidime–avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases

(2015) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains

(2015) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013

(2015) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies

(2015) Henri Merdjan et al.   CLINICAL DRUG INVESTIGATION

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

(2015) Antoine Tarral et al.   CLINICAL THERAPEUTICS

Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint forStaphylococcus aureus: the role of PBP2a in the activity of ceftaroline

(2015) Sushmita D. Lahiri et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VivoEfficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates

(2014) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

(2014) Henry Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases

(2014) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012

(2014) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance

(2014) S. D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

(2014) Ken Coleman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination therapy for carbapenem-resistant Gram-negative bacteria

(2014) M. Paul et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam activity against extended-spectrum AmpC  -lactamases

(2014) N. Porres-Osante et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)

(2014) R. K. Flamm et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Proliferation and significance of clinically relevant β-lactamases

(2013) Karen Bush   Annals of the New York Academy of Sciences

Correlations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae

(2013) Milena McLaughlin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World

(2013) Sarah M. Drawz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model

(2013) Seth T. Housman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases

(2013) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia

(2013) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Susceptibility of Inpatient Urinary Tract Isolates of Gram-Negative Bacilli in the United States: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009−2011

(2013) Sam K. Bouchillon et al.   CLINICAL THERAPEUTICS

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005–2010

(2013) Tim Babinchak et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Management of Urinary Tract Infections From Multidrug-Resistant Organisms

(2013) Kalpana Gupta et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam

(2013) Shampa Das et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Carbapenemase-producing Enterobacteriaceae: Overview of a major public health challenge

(2013) P. Nordmann   MEDECINE ET MALADIES INFECTIEUSES

2013 WSES guidelines for management of intra-abdominal infections

(2013) Massimo Sartelli et al.   World Journal of Emergency Surgery

ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

(2012) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

(2012) Elizabeth B. Hirsch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia

(2012) A. E. Muller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tracking a Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae with Whole-Genome Sequencing

(2012) E. S. Snitkin et al.   Science Translational Medicine

Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases

(2011) P. R. S. Lagacé-Wiens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

(2011) Z. Aktaş et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa

(2011) Souha S. Kanj et al.   MAYO CLINIC PROCEEDINGS

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam  -Lactamase Inhibitor

(2010) T. Stachyra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae

(2010) Andrea Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of NXL104 in Combination with  -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases

(2009) A. Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

(2008) Helen W. Boucher et al.   CLINICAL INFECTIOUS DISEASES

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum  -lactamases and carbapenemases

(2008) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY